Document is current
Any future updates will be listed below
-
Authors
Perkins, Diana O. https://orcid.org/0000-0001-9396-2206
Jeffries, Clark D. https://orcid.org/0000-0002-3044-2649
Clark, Scott R. https://orcid.org/0000-0003-1640-5611
Upthegrove, Rachel https://orcid.org/0000-0001-8204-5103
Wannan, Cassandra M. J. https://orcid.org/0000-0003-1317-4635
Wray, Naomi R. https://orcid.org/0000-0001-7421-3357
Li, Qingqin S.
Do, Kim Q. https://orcid.org/0000-0003-1968-1646
Walker, Elaine https://orcid.org/0000-0002-9798-8101
Paul Amminger, G.
Anticevic, Alan
Cotter, David https://orcid.org/0000-0003-4308-0648
Ellman, Lauren M.
Mongan, David https://orcid.org/0000-0001-7931-9636
Phassouliotis, Christina
Barbee, Jenna
Roth, Sharin
Billah, Tashrif
Corcoran, Cheryl https://orcid.org/0000-0002-8902-4353
Calkins, Monica E.
Cerrato, Felecia
Khadimallah, Ines
Klauser, Paul https://orcid.org/0000-0003-0284-4947
Winter-van Rossum, Inge
Nunez, Angela R.
Bleggi, Rachel S.
Martin, Alicia R.
Bouix, Sylvain https://orcid.org/0000-0003-1326-6054
Pasternak, Ofer
Shah, Jai L. https://orcid.org/0000-0002-7549-6990
Toben, Catherine
Wolf, Daniel H. https://orcid.org/0000-0002-9731-8781
,
Kahn, Rene S. https://orcid.org/0000-0001-5909-8004
Kane, John M.
McGorry, Patrick D.
Bearden, Carrie E. https://orcid.org/0000-0002-8516-923X
Nelson, Barnaby
Shenton, Martha E. https://orcid.org/0000-0003-4235-7879
Woods, Scott W. https://orcid.org/0000-0002-3103-5228
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01MH124639, U01MH124631, U01MH124631, U01MH124631, U01MH124631, U01MH124631, U01MH124639, U01MH124631, U01MH124639, U01MH124631, U01MH124639, U01MH124631,, U01MH124639, U24MH124629, U01MH124631, U24MH124629, U01MH124639, U24MH124629, U24MH124629, U01MH124639, U01MH124639, U24MH124629, U24MH124629, U24MH124629, U01MH124639, U01MH124631, U01MH124639, U24MH124629,, U01MH124631, U01MH124631, U01MH124631, U24MH124629, U01MH124639)
- License Information
-
More Information
Article History
Received: 16 September 2024
Accepted: 11 February 2025
First Online: 21 May 2025
Competing interests
: The authors declare the following competing interests: DOP had served on an advisory board for Alkermes. SRC has participated in advisory and educational boards and received speaker’s fees from Janssen- Cilag, Lundbeck-Otsuka, and Servier; Research funding from Janssen-Cilag, Lundbeck-Otsuka, Gilead and XWPharma; Data sharing from Viatris Australia. KA is on the Australian Cognitive Impairment Associated with Schizophrenia Advisory Board for Boehringer Ingelheim and receives honorary funds; DD has received honorary funds for one educational seminar for CSL Sequiris; AA is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc.; and is a coinventor on the following patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for NeuroBehavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019; EC has received speaker fees at non-promotional educational events; PFP has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Proxymm Science, Otsuka, outside the current study; JK has received speaking or consulting fees from Janssen, Boehringer Ingelheim, ROVI and Lundbeck; CDC has received grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation and honoraria or travel support from Angelini, Janssen, and Viatris; RU has received speaker fees at non promotional educational event: Otsuka: Consultancy for Viatris and Springer Healthcare. Honorary General Secretary British Association for Psychopharmacology (unpaid); JMK is a consultant to or receives honoraria and/or travel support and/or speakers bureau: Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Meyer-Squibb, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, Teva; RSK provides consulting to Alkermes, Boehringer-Ingelheim; SWW has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. He owns stock in NW PharmaTech; CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda; GDH has been a consultant for Bristol Myers Squibb; PJM has been a consultant for Otsuka and TEVA; and ZT has been a consult for Manifest Technologies. All other authors report no competing interests. CMC is an Associate Editor of Schizophrenia.
